Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more modest valuations. Mid-cap stocks represent companies valued at between $2 billion and $10 billion. If they give investors a reason to be bullish on their growth prospects or show that they're on the right path, these types of investments can double in value and be 10-baggers in the long run.To be clear, it doesn't always work out that way, and there are risks with these types of stoc ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of ...

Background and Expertise - The analyst has a strong background in life sciences with a PhD in Bioengineering and over 20 years of experience in the research and development of novel Cell & Gene Therapies (CGT) [2] - The analyst focuses on analyzing biotechnology, pharmaceutical, Medtech, and healthcare stocks, leveraging their expertise to assess the potential of novel treatments and their impact on shareholder returns [2] Disclosure and Independence - The analyst has no stock, option, or similar derivative positions in any of the companies mentioned and no plans to initiate any such positions within the next 72 hours [1] - The analyst is not receiving compensation for the article other than from Seeking Alpha and has no business relationship with any company whose stock is mentioned [1] - The analyst is associated with another Seeking Alpha contributor, "Euro Invest," but each works independently and adheres to Seeking Alpha's Shared Association Guidelines [2]

Industry Overview - Companies in synthetic biology engineer biological systems for applications in pharmaceuticals and agriculture, utilizing genetic engineering and biotechnology techniques to create novel organisms and processes, with significant growth potential in curing genetic diseases and extending human lifespan [1] - The genomics and synthetic biology sectors are attracting substantial interest from venture capitalists and institutional investors due to their potential for innovation and tailored treatments based on genetic makeup [8][21] Company Highlights - CRISPR Therapeutics is leveraging its CRISPR/Cas9 gene-editing platform to develop therapies for hemoglobinopathies, cancer, and diabetes, achieving a milestone with the first-ever approval for a CRISPR/Cas9 gene-edited therapy, Casgevy, in the UK for treating sickle cell disease and transfusion-dependent beta-thalassemia [3][12][23] - Monte Rosa Therapeutics is focused on developing small-molecule precision medicines that utilize the body's mechanisms to selectively degrade proteins relevant to various diseases, including MYC-driven tumors and autoimmune diseases [5][11] - Immunocore Holdings is developing a novel class of T cell receptor bispecific immunotherapies for cancer and autoimmune diseases, with its product KIMMTRAK already in use for treating unresectable or metastatic uveal melanoma [13][25] Price Target and Upside Potential - The average short-term price target for CRISPR Therapeutics indicates a potential increase of 136.7% from the last closing price of $28.32, with a maximum upside of 253.1% and a downside of 15.3% [4] - Monte Rosa Therapeutics has a projected price target increase of 161.1% from a closing price of $6.93, suggesting a maximum upside of 188.6% with no downside [14] - Rigel Pharmaceuticals shows a potential price increase of 82.1% from a closing price of $17.09, with a maximum upside of 233.5% and a downside of 18.1% [18] - Castle Biosciences has a projected price target increase of 51.4% from a closing price of $27.53, indicating a maximum upside of 81.6% with no downside [20] Investment Recommendations - Five small and mid-sized genomics and synthetic biology stocks are recommended for investment, including CRISPR Therapeutics, Immunocore Holdings, Monte Rosa Therapeutics, Rigel Pharmaceuticals, and Castle Biosciences, all carrying favorable Zacks Ranks [7][9]

Core Viewpoint - CRISPR Therapeutics has faced a significant decline in stock value, down 23% year to date, despite recent regulatory approvals for its gene-editing medicine, Casgevy [1] Regulatory Approvals - Since November 2023, CRISPR Therapeutics has received approvals for Casgevy in multiple regions, including the U.S., U.K., European Union, Saudi Arabia, and Bahrain [2] Market Potential and Pricing - Casgevy is priced at $2.2 million in the U.S., targeting a market of approximately 35,000 patients in the U.S. and Europe, but high costs may limit accessibility [3] - In the U.S., around 100,000 people have sickle cell disease (SCD), with an estimated 50% to 60% on Medicaid, which may enhance access to Casgevy through government initiatives [4][11] - The potential market for Casgevy also includes about 23,000 patients in Saudi Arabia and Bahrain [20] Financial Outlook - Analysts project that Casgevy's peak annual sales could exceed $2.2 billion, with CRISPR entitled to 40% of the profits from the medicine [18] - In the first nine months of the year, CRISPR reported revenue of approximately $1.6 million, indicating slow uptake of Casgevy [21] Competitive Landscape - CRISPR Therapeutics faces competition from Bluebird Bio, which has alternative treatments for SCD and transfusion-dependent beta-thalassemia (TDT), but CRISPR and Vertex have more financial resources [7] - The company has less competition in Europe and the Middle East, presenting a multibillion-dollar revenue opportunity for Casgevy [15] Future Developments - The Biden administration's initiative to assist Medicaid patients in affording Casgevy is expected to improve access and could facilitate future approvals for other gene-editing therapies [5][11][13] - CRISPR Therapeutics is also developing additional gene-editing programs, including investigational cancer treatments and a potential cure for type 1 diabetes [13] Innovation and Validation - The development of Casgevy has validated CRISPR Therapeutics' gene-editing platform, suggesting that the company may achieve more clinical and regulatory successes in the next five years [8]

CRISPR Therapeutics (CRSP -1.64%) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first commercialized therapy and a promising pipeline that's continuing to deliver, this biotech is on track for growth. Plus, investors just got another big green flag to invest in its stock.Here's what you need to know.This new development augurs a bright futurePer the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the Food and Drug Administr ...

Innovation holds the key in the ever-evolving biotech sector, and most companies in this sector are striving to develop a drug or treatment using a breakthrough technology.Biotech companies with promising gene therapies in their portfolio/pipeline have garnered investors’ attention in 2024. Interest in this space renewed following the FDA approval of a few gene therapies toward the end of 2023.Consequently, some pharma/biotech bigwigs scurried for a lucrative catch in the space, either through licensing dea ...

Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025.The Food and Drug Administration (FDA) approved CRISPR Therapeutics' (CRSP 1.05%) first treatment last December, and its successful launch could push the stock much higher.  Investment bank analysts also expect Iovance Biotherapeutics (IOVA 0.13%) to soar in 2025.Before chasing exciting price targets, thou ...

CRISPR Therapeutics (CRSP -3.57%) is recognized as a pioneer in the field of gene therapy. This biotechnology has the potential to revolutionize medicine through precise modifications of a person's DNA to treat and cure genetic diseases. In 2023, the company's Casgevy product for sickle cell disease became the first-ever CRISPR-based therapy approved by the Food and Drug Administration (FDA) as an important company milestone.Nevertheless, commercialization has been slow, with the market already waiting for ...

Shares of CRISPR Therapeutics AG (CRSP) have gained 0.8% over the past four weeks to close the last trading session at $51.17, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $81 indicates a potential upside of 58.3%.The mean estimate comprises 24 short-term price targets with a standard deviation of $34.31. While the lowest estimate of $30 indicates a 41.4% decline from the cur ...